2019 American Transplant Congress
Preemptive Therapy is Cost Effective When Compared to Prophylaxis in Cytomegalovirus Donor Positive – Recipient Negative Liver Transplant Recipients
*Purpose: To compare the cost effectiveness of preemptive therapy (PET) vs prophylaxis for the prevention of cytomegalovirus (CMV) in high-risk donor seropositive/recipient seronegative (D+R-) liver…2019 American Transplant Congress
The Association Of Frailty With Risk Of Cytomegalovirus And BK Infection
*Purpose: Opportunistic infections are responsible for significant morbidity and mortality post-kidney transplant (KT). Recently, medical frailty has been recognized to increase the risk of death…2019 American Transplant Congress
A Cytomegalovirus Antiviral Stewardship Program at a Large Transplant Center
*Purpose: The purpose of this study was to determine the feasibility and scope of a multidisciplinary cytomegalovirus Antiviral Stewardship Program.*Methods: The principles of antimicrobial stewardship…2019 American Transplant Congress
Evolution of HHV6- and CMV-Specific T Cell Functional Responses and Immune Cell Populations after Kidney Transplant
*Purpose: Human herpesvirus (HHV)-6 reactivation after solid organ or hematopoietic stem cell transplant has been associated with complications such as graft rejection and all-cause mortality.…2019 American Transplant Congress
Evaluation of Rabbit Antithymocyte Globulin (rATG) Dosing and Incidence of Opportunistic Viral Infections in Kidney Transplant Recipients Using Tacrolimus (TAC), Mycophenolate (MPA) and Steroid Free Maintenance Immunosuppression
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: There is limited literature evaluating rATG dosing and incidence of infection with TAC/MPA and early steroid withdrawal. This study evaluates rATG dosing and overall…2019 American Transplant Congress
Healthcare Resource Utilization and Associated Costs of Cytomegalovirus Management among Solid Organ Transplant Recipients
1Analysis Group, Inc., Boston, MA, 2Johns Hopkins University, Baltimore, MD, 3Shire, Cambridge, MA
*Purpose: Solid organ transplant (SOT) recipients who develop cytomegalovirus (CMV) infection and disease are at increased risk of morbidity. We quantified real-world healthcare resource utilization…2019 American Transplant Congress
Differences in CMV-Specific CD4 T Cell Population in De Novo Kidney Transplant Recipients Treated with Everolimus-Based Regimen Compared to a Standard Tacrolimus-MPA Regimen: Results from ATHENA
1ATHENA, CMV Substudy Group, Germany, 2Novartis, Pharma GmbH, Germany
*Purpose: The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard regimen of mycophenolic…2019 American Transplant Congress
Low-Dose Valacyclovir Prophylaxis for Cytomegalovirus Infection in Renal Transplant Recipients with Intermediate Risk
*Purpose: According to recent guidelines ganciclovir or valganciclovir chemoprophylaxis is recommended for all kidney transplantation (KT) recipients (except for D-/R- serology) for preventing cytomegalovirus (CMV)…2019 American Transplant Congress
Retrospective Evaluation of Optimal Cmv Prophylaxis Regimens in Lung Transplant Patients: Analysis of Patient Outcomes Pre and Post Protocol Dosing Alterations
St. Joseph Hospital and Medical Center, Phoenix, AZ
*Purpose: Given the heightened risk of cytomegalovirus (CMV) following lung transplantation compared to other solid organ transplants, with minimal evidence based guidance specific to this…2019 American Transplant Congress
IE-1 Specific T Cell Receptor Repertoire Diversity and Protection against CMV Reactivation
*Purpose: Cytomegalovirus (CMV) is a major complication for organ transplant recipients. T cells reacting to the CMV antigen immediate-early (IE-1) are key in controlling reactivation…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 33
- Next Page »